Novo Holdings's Therapeutics Portfolio

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

Tribune Therapeutics specializes in building promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer.

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Asgard Therapeutics is a Biotechnology Company.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.

Booster Therapeutics is a biotech company that offers regulation of cellular homeostasis, as well as develops medicines for aging diseases.

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.

Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.